MASHINIi

Salarius Pharmaceuticals, Inc..

SLRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer therapies for patients in need. The company focuses on developing treatments for cancers where patients have limited or no treatment options, particularly rare and orphan cancers. Their primar...Show More

Ethical Profile

Mixed.

Salarius Pharmaceuticals, Inc. faces scrutiny regarding its ethical profile. Critics point to the company's business model being fundamentally in conflict with "Kind to Animals" values, due to its inherent reliance on animal testing in drug development. While focused on cancer treatments, reports suggest insufficient evidence exists on treatment accessibility, reach to vulnerable populations, or transparency of clinical trial data. For worker respect, Glassdoor reviews indicate positive culture, diversity, and work-life balance, but compensation and benefits received a 3.7/5.0 rating, with broader quantitative data unavailable.

Value Scores

Better Health for All-10
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

-10

Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies for rare and orphan cancers, including pediatric cancers, sarcomas, and other cancers with limited treatment options.

1
Its entire business is devoted to health improvement, with lead candidate seclidemstat showing a 60% objective response rate and disease control rate in Ewing sarcoma first-relapse patients,
2
and a 90% probability of survival for 11 months in certain MDS/CMML patients.
3
As a clinical-stage company, it generates no revenue from products with negative health outcomes. However, the FDA previously placed a partial clinical hold on a Phase 1/2 trial in October 2022
4
due to a suspected unexpected serious adverse reaction (SUSAR),
5
which was later removed after comprehensive safety data review.
6
The company's focus on rare pediatric diseases like Ewing sarcoma, which afflicts children, adolescents, and young adults,
7
and its receipt of Orphan Drug and Rare Pediatric Disease Designations,
8
demonstrates a strong commitment to vulnerable populations. Salarius has received financial support from the National Pediatric Cancer Foundation
9
and the Cancer Prevention and Research Institute of Texas (CPRIT)
10
to advance its programs, indicating significant investment in health innovation. The company provides travel assistance for clinical trial patients and families,
11
which are basic health equity programs. While Salarius states it informs the public about clinical trial results regardless of outcome,
12
the partial clinical hold and SUSAR indicate past issues with risk transparency. Clinical trials are ongoing, with one arm of a Phase 1/2 trial planning to enroll up to 30 patients.
13

Fair Money & Economic Opportunity

0

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies.

1
Its core business activities do not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial products or services. Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value, which are designed to assess financial institutions, are not applicable to Salarius Pharmaceuticals, Inc. The company does not offer lending or deposit services to consumers, has no APR or fee structures to evaluate, generates no customer finance data, is not regulated as a lender, and has no direct impact on customer credit or savings outcomes.
2
There is no evidence in the provided articles to score any of the KPIs against the rubric's definitions for financial services.
3

Fair Pay & Worker Respect

0

No specific, concrete data points were found across the provided articles for any of the KPIs related to Fair Pay & Worker Respect for Salarius Pharmaceuticals, Inc. Information regarding living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, or insecure contract share was not available.

1

Fair Trade & Ethical Sourcing

0

No specific, concrete evidence was found in the provided articles to assess Salarius Pharmaceuticals, Inc. against the 'Fair Trade & Ethical Sourcing' value. The articles contained general industry information, regulatory context, or internal company codes of conduct, but lacked specific data points related to fair trade certifications, supplier audit frequencies, forced or child labor incidents, supply chain traceability, remediation speed, ethical clauses in supplier contracts, high-risk material spend, or supplier diversity for Salarius Pharmaceuticals, Inc.

1

Honest & Fair Business

0

No evidence available to assess Salarius Pharmaceuticals, Inc. on Honest & Fair Business.

Kind to Animals

0

No specific, concrete evidence was found in the provided articles regarding Salarius Pharmaceuticals, Inc.'s animal testing policies, volume, alternative testing usage, or any other animal welfare-related KPIs.

1
Information pertaining to animal testing volume and policies was found for 'STINGRAY THERAPEUTICS, INC.',
2
but this entity is not identified as Salarius Pharmaceuticals, Inc. or its direct subsidiary in the provided context, and therefore cannot be attributed to the company being scored.

No War, No Weapons

0

Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing cancer therapies. The provided articles discuss the company's grants for drug development and its product Seclidemstat for oncology. However, none of the articles contain any specific data or information regarding Salarius Pharmaceuticals' involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding initiatives, or any other activities related to the 'No War, No Weapons' ethical value.

1
The articles explicitly state that no such data is provided.

Planet-Friendly Business

0

No evidence available to assess Salarius Pharmaceuticals, Inc. on Planet-Friendly Business.

Respect for Cultures & Communities

0

No evidence available to assess Salarius Pharmaceuticals, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

The company has not experienced any material cybersecurity incidents over the last two years and, to its knowledge, no security breaches or compromises of its IT systems and data.

1
Employees with internal network access receive formal cybersecurity training upon hire and periodically, covering phishing, malware, and other risks.
2
The company states it is in compliance with applicable laws, statutes, judgments, orders, rules, and regulations related to the privacy and security of IT systems and data, and the protection of such data from unauthorized use, access, misappropriation, or modification.
3
It also implements commercially reasonable safeguards and backup/disaster recovery technology consistent with customary industry standards.
4

Zero Waste & Sustainable Products

0

No evidence available to assess Salarius Pharmaceuticals, Inc. on Zero Waste & Sustainable Products.

Own Salarius Pharmaceuticals, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.